Download PDF
Nervenheilkunde 2020; 39(06): 397-403
DOI: 10.1055/a-1134-5345
Schwerpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Therapien bei der chronisch inflammatorischen demyelinisierenden Polyneuropathie

Treatment of chronic inflammatory demyelinating polyneuropathy
Stefan Gingele∗
1   Klinik für Neurologie, Medizinische Hochschule Hannover
,
Tabea Seeliger∗
1   Klinik für Neurologie, Medizinische Hochschule Hannover
,
Thomas Skripuletz
1   Klinik für Neurologie, Medizinische Hochschule Hannover
› Author Affiliations
Further Information

Publication History

Publication Date:
04 June 2020 (online)

    Permissions and Reprints

ZUSAMMENFASSUNG

Die chronisch inflammatorische demyelinisierende Polyneuropathie (CIDP) ist eine behandelbare Erkrankung des peripheren Nervensystems. Ein schneller Therapiebeginn kann bei vielen Patienten zu einer Erkrankungsstabilisierung führen und somit körperliche Behinderungen lindern oder verbessern. Steroide, intravenöse Immunglobuline und Plasmaaustausch können initial eingesetzt werden. Seit 2018 steht eine Behandlung mit subkutanen Immunglobulinen zur Verfügung. Patienten, die sich unter der Behandlung mit intravenösen Immunglobulinen stabilisiert haben, können auf diese neue Therapieform umgestellt werden. Subkutane Immunglobuline bieten viele Vorteile, wie beispielsweise größere Flexibilität im Alltag durch die Möglichkeit der Heimbehandlung, und sie eignen sich deshalb besonders gut für die Langzeitbehandlung von CIDP-Patienten.

ABSTRACT

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable disease of the peripheral nervous system. Most patients benefit from a quick treatment initiation which promotes reduced disability. The three treatment options steroids, intravenous immunoglobulins, and plasma exchange can be used as initial therapy. Since 2018 subcutaneous immunoglobulins are available as additional therapy for patients with CIDP. Patients who responded to intravenous immunoglobulin treatment can be transitioned to this new therapy. Subcutaneous immunoglobulins have some advantages including a better flexibility of daily life and are thus especially suitable for a long term treatment in patients with CIDP.

Schlüsselwörter

CIDP - Immunneuropathie - Autoimmunerkrankung - Immunglobuline - IVIG - SCIG

Key words

CIDP - immune mediated neuropathy - autoimmme disease - immunoglobulins - IVIG - SCIG
 

  • Literatur

  • 1 Lehmann HC, Burke D, Kuwabara S.. Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2019; 90: 981-7 doi:10.1136/jnnp-2019-320314
    CrossrefPubMedGoogle Scholar
  • 2 Grimm A, Axer H. Chronisch immunvermittelte Neuropathien – Diagnostik und Therapie. Fortschr Neurol Psychiatr 2018; 86: 439-52 doi:10.1055/s-0044-101831
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Schlotter-Weigel B, Senderek J.. Immune-mediated/­inflammatory and hereditary neuropathies – Overview and diagnostic ­algorithm. Fortschritte der Neurol Psychiatr 2018; 86: 566-74 doi:10.1055/a-0655-7659
    Google Scholar
  • 4 van Schaik IN, Bril V, van Geloven N. et al Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2018; 17: 35-46 doi:10.1016/S1474-4422(17)30378-2
    CrossrefPubMedGoogle Scholar
  • 5 Dyck PJ, O’Brien PC, Oviatt KF. et al Prednisone improves ­chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-41 doi:10.1002/ana.410110205
    CrossrefPubMedGoogle Scholar
  • 6 van Schaik IN, Eftimov F, van Doorn PA. et al Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9: 245-53 doi:10.1016/S1474-4422(10)70021-1
    CrossrefPubMedGoogle Scholar
  • 7 Lopate G, Pestronk A, Al-Lozi M.. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005; 62: 249-54 doi:10.1001/archneur.62.2.249
    CrossrefPubMedGoogle Scholar
  • 8 Stangel M, Gold R. [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010]. Nervenarzt 2011; 82: 415-6 doi:10.1007/s00115-010-3059-8
    CrossrefPubMedGoogle Scholar
  • 9 Vermeulen M, van der Meché FG, Speelman JD. et al Plasma and ­gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985; 70: 317-26 doi:10.1016/0022-510x(85)90173-x
    CrossrefPubMedGoogle Scholar
  • 10 Eftimov F, Winer JB, Vermeulen M. et al Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013; 2013: CD001797 doi:10.1002/14651858.CD001797.pub3
    Google Scholar
  • 11 Hughes RAC, Donofrio P, Bril V. et al Intravenous immune globulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008; 7: 136-44 doi:10.1016/S1474-4422(07)70329-0
    CrossrefPubMedGoogle Scholar
  • 12 Adrichem ME, Eftimov F, van Schaik IN. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuro­pathy, a time to start and a time to stop. J Peripher Nerv Syst 2016; 21: 121-7 doi:10.1111/jns.12176
    CrossrefPubMedGoogle Scholar
  • 13 Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. In: Clinical and Experimental Immunology, Supplement. 1994: 79-83
    Google Scholar
  • 14 Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013; 27: 171-8 doi:10.1016/j.tmrv.2013.05.004
    CrossrefPubMedGoogle Scholar
  • 15 Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008; 28: 803-19 ix doi:10.1016/j.iac.2008.06.006
    CrossrefPubMedGoogle Scholar
  • 16 Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases. Curr Opin Allergy Clin Immunol 2011; 11: 532-8 doi:10.1097/ACI.0b013e32834c22da
    CrossrefPubMedGoogle Scholar
  • 17 Cocito D, Merola A, Peci E. et al Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. J Neurol 2014; 261: 2159-64 doi:10.1007/s00415-014-7444-2
    CrossrefPubMedGoogle Scholar
  • 18 Markvardsen LH, Christiansen I, Andersen H. et al Headache and Nausea after Treatment with High-Dose Subcutaneous versus Intravenous Immunoglobulin. Basic Clin Pharmacol Toxicol 2015; 117: 409-12 doi:10.1111/bcpt.12428
    CrossrefPubMedGoogle Scholar
  • 19 Hadden RDM, Marreno F.. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Ther Adv Neurol Disord 2015; 8: 14-9 doi:10.1177/1756285614563056
    CrossrefPubMedGoogle Scholar
  • 20 Markvardsen LH, Debost J-C, Harbo T. et al Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2013; 20: 836-42 doi:10.1111/ene.12080
    CrossrefPubMedGoogle Scholar
  • 21 Köller H, Schroeter M, Feischen H. et al Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J Neurol 2006; 253: 1505-6 doi:10.1007/s00415-006-0258-0
    CrossrefPubMedGoogle Scholar
  • 22 Cocito D, Serra G, Falcone Y. et al The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J Peripher Nerv Syst 2011; 16: 150-2 doi:10.1111/j.1529-8027.2011.00340.x
    CrossrefPubMedGoogle Scholar
  • 23 Yoon M-S, Gold R, Kerasnoudis A.. Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders. Ther Adv Neurol Disord 2015; 8: 153-9 doi:10.1177/1756285615584739
    CrossrefPubMedGoogle Scholar
  • 24 Leussink VI, Hartung HP, Kieseier BC. et al Subcutaneous immuno­globulins in the treatment of chronic immune-mediated neuropathies. Ther Adv Neurol Disord 2016; 9: 336-43 doi:10.1177/1756285616641583
    CrossrefPubMedGoogle Scholar
  • 25 Dyck PJ, Litchy WJ, Kratz KM. et al A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36: 838-45 doi:10.1002/ana.410360607
    CrossrefPubMedGoogle Scholar
  • 26 Hahn AF, Bolton CF, Pillay N. et al Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119: 1055-66 doi:10.1093/brain/119.4.1055
    CrossrefPubMedGoogle Scholar
  • 27 Galldiks N, Burghaus L, Dohmen C. et al Immunoadsorption in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy with Unsatisfactory Response to First-Line Treatment. Eur Neurol 2011; 66: 183-9 doi:10.1159/000331011
    CrossrefPubMedGoogle Scholar
  • 28 Dorst J, Ludolph AC, Senel M. et al Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients. J Neurol 2018; 265: 2906-15 doi:10.1007/s00415-018-9082-6
    CrossrefPubMedGoogle Scholar
  • 29 Jiménez C, Rosenow F, Grieb P. et al Adsorption therapy with tryptophan-conjugated polyvinyl alcohol gels in 10 patients with acute ­Guillain-Barré syndrome. Transfus Sci 1993; 14: 9-11 doi:10.1016/0955-3886(93)90046-W
    CrossrefPubMedGoogle Scholar
  • 30 Grob D, Simpson D, Mitsumoto H. et al Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995; 45: 338-44 doi:10.1212/WNL.45.2.338
    CrossrefPubMedGoogle Scholar
  • 31 Köhler W, Bucka C, Klingel R.. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 2011; 26: 347-55 doi:10.1002/jca.20317
    CrossrefPubMedGoogle Scholar
  • 32 Dyck PJ, O’Brien P, Swanson C. et al Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985; 35: 1173-6 doi:10.1212/wnl.35.8.1173
    CrossrefPubMedGoogle Scholar
  • 33 Mahdi-Rogers M, Brassington R, Gunn AA. et al ­Immunomodulatory treatment other than corticosteroids, immunoglobulin and ­plasma exchange for chronic inflammatory demyelinating polyradiculo­neuropathy. Cochrane database Syst Rev 2017; 5: CD003280 doi:10.1002/14651858.CD003280.pub5
    PubMedGoogle Scholar
  • 34 Mahdi-Rogers M, Rutterford C, Hughes RAC. et al Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009; 8: 158-64 doi:10.1016/S1474-4422(08)70299-0
    CrossrefPubMedGoogle Scholar
  • 35 Interest of Mycophenolate for CIDP Weaning – Full Text View – ClinicalTrials.gov. Im Internet https://clinicaltrials.gov/ct2/show/NCT02494505 Stand: 08.03.2020
    Google Scholar
  • 36 Nobile-Orazio E, Cocito D, Jann S. et al Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: A randomised controlled trial. Lancet Neurol 2012; 11: 493-502 doi:10.1016/S1474-4422(12)70093-5
    CrossrefPubMedGoogle Scholar
  • 37 Nobile-Orazio E, Cocito D, Jann S. et al Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methyl­prednisolone in CIDP. J Neurol Neurosurg Psychiatry 2015; 86: 729-34 doi:10.1136/jnnp-2013-307515
    CrossrefPubMedGoogle Scholar
  • 38 Wenninger S, Schoser B. Intravenöse Immunglobuline sind die ­Therapie der ersten Wahl bei der CIDP. Aktuelle Neurol 2014; 41: 173-7 doi:10.1055/s-0034-1369895
    Article in Thieme ConnectGoogle Scholar
  • 39 Benedetti L, Briani C, Franciotta D. et al Rituximab in patients with chronic inflammatory demyelinating polyra diculoneuropathy: A report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82: 306-8 doi:10.1136/jnnp.2009.188912
    CrossrefPubMedGoogle Scholar
  • 40 Roux T, Debs R, Maisonobe T. et al Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. J Peripher Nerv Syst 2018; 23: 235-40 doi:10.1111/jns.12287
    CrossrefPubMedGoogle Scholar
  • 41 Gingele S, Jacobus T, Konen F. et al Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients. Cells 2018; 8: 12 doi:10.3390/cells8010012
    CrossrefPubMedGoogle Scholar
  • 42 Seeliger T, Prenzler NK, Gingele S. et al Neuro-Sjögren: Peripheral Neuropathy With Limb Weakness in Sjögren’s Syndrome. Front Immunol 2019; 10: 1600 doi:10.3389/fimmu.2019.01600
    CrossrefPubMedGoogle Scholar
  • 43 Mahdi-Rogers M, van Doorn PA, Hughes RAC. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane database Syst Rev 2013; 2013: CD003280 doi:10.1002/14651858.CD003280.pub4
    Google Scholar
  • 44 Good JL, Chehrenama M, Mayer RF. et al Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 51: 1735-8 doi:10.1212/wnl.51.6.1735
    CrossrefPubMedGoogle Scholar
  • 45 Brannagan TH, Pradhan A, Heiman-Patterson T. et al High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002; 58: 1856-8 doi:10.1212/wnl.58.12.1856
    CrossrefPubMedGoogle Scholar
  • 46 Pitarokoili K, Yoon MS, Kröger I. et al Severe refractory CIDP: a case series of 10 patients treated with bortezomib. J Neurol 2017; 264: 2010-20 doi:10.1007/s00415-017-8599-4
    CrossrefPubMedGoogle Scholar
  • 47 Hughes R, Bensa S, Willison H. et al Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001; 50: 195-201 www.ncbi.nlm.nih.gov/pubmed/11506402 Stand: 07.03.2020
    CrossrefPubMedGoogle Scholar
  • 48 Van Nes SI, Vanhoutte EK, Van Doorn PA. et al Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011; 76: 337-45 doi:10.1212/WNL.0b013e318208824b
    CrossrefPubMedGoogle Scholar
  • 49 Draak THP, Vanhoutte EK, Van Nes SI. et al Changing outcome in inflammatory neuropathies Rasch-cooparative responsiveness. Neurology 2014; 83: 2124-32 doi:10.1212/WNL.0000000000001044
    CrossrefPubMedGoogle Scholar